NCT04002830 - A Multicenter, Safety and Efficacy Study of Taliglucerase Alfa in Subjects With Type 3 Gaucher Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

July 30, 2023

Study Completion Date

July 30, 2023

Conditions

Gaucher Disease, Type 3

Interventions

DRUG

Elelyso

Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.

Trial Locations (3)

9103102

Shaare Zedek Medical Center, Jerusalem

Unknown

All India Institute of Medical Sciences, New Delhi

Gazi University, Ankara